Ackerman Shelley E, Currier Nicolas V, Bergen Jamie M, Cochran Jennifer R
Department of Bioengineering, Stanford University, Shriram Center, 443 Via Ortega, Stanford, CA 94305, USA.
Expert Rev Proteomics. 2014 Oct;11(5):561-72. doi: 10.1586/14789450.2014.932251. Epub 2014 Aug 28.
Cystine-knot miniproteins, also known as knottins, constitute a large family of structurally related peptides with diverse amino acid sequences and biological functions. Knottins have emerged as attractive candidates for drug development as they potentially fill a niche between small molecules and protein biologics, offering drug-like properties and the ability to bind to clinical targets with high affinity and selectivity. Due to their extremely high stability and unique structural features, knottins also demonstrate promise in addressing challenging drug development goals, including the potential for oral delivery and the ability to access intracellular drug targets. Several naturally-occurring knottins have recently received approval for treating chronic pain and irritable bowel syndrome, while others are under development for tumor imaging applications. To expand beyond nature's repertoire, rational and combinatorial protein engineering methods are generating tumor-targeting knottins for use as cancer diagnostics and therapeutics.
胱氨酸结微型蛋白,也称为结蛋白,构成了一个结构相关的肽大家族,其氨基酸序列和生物学功能各不相同。结蛋白已成为药物开发的有吸引力的候选物,因为它们可能填补小分子和蛋白质生物制剂之间的空白,具有类似药物的特性,并能够以高亲和力和选择性结合临床靶点。由于其极高的稳定性和独特的结构特征,结蛋白在实现具有挑战性的药物开发目标方面也显示出前景,包括口服给药的可能性以及进入细胞内药物靶点的能力。几种天然存在的结蛋白最近已获批准用于治疗慢性疼痛和肠易激综合征,而其他一些则正在开发用于肿瘤成像应用。为了超越自然界的范围,合理的和组合的蛋白质工程方法正在产生用于癌症诊断和治疗的肿瘤靶向结蛋白。